Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Total Current Liabilities (2018 - 2025)

Addex Therapeutics' Total Current Liabilities history spans 8 years, with the latest figure at $1.5 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 63.84% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 63.84% increase, with the full-year FY2025 number at $1.4 million, up 57.94% from a year prior.
  • Total Current Liabilities came in at $1.5 million for Q4 2025, up from $1.5 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $5.3 million in Q1 2024, with the low at $915606.7 in Q4 2024.
  • Historically, Total Current Liabilities has averaged $3.0 million across 5 years, with a median of $3.3 million in 2022.
  • Peak annual rise in Total Current Liabilities hit 63.84% in 2025, while the deepest fall reached 77.96% in 2025.
  • Year by year, Total Current Liabilities stood at $4.5 million in 2021, then decreased by 24.03% to $3.4 million in 2022, then fell by 4.26% to $3.3 million in 2023, then crashed by 71.93% to $915606.7 in 2024, then skyrocketed by 63.84% to $1.5 million in 2025.
  • Business Quant data shows Total Current Liabilities for ADXN at $1.5 million in Q4 2025, $1.5 million in Q3 2025, and $1.4 million in Q2 2025.